NASDAQ:AXGT - Axovant Gene Therapies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.19 -0.33 (-4.39 %) (As of 05/24/2019 04:00 PM ET)Previous Close$7.52Today's Range$7.00 - $7.625052-Week Range$7.00 - $52.72Volume394,536 shsAverage Volume264,142 shsMarket Capitalization$163.79 millionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd. Receive AXGT News and Ratings via Email Sign-up to receive the latest news and ratings for AXGT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGT Previous Symbol CUSIPN/A CIKN/A Webhttp://www.axovant.com/ Phone44-20-3318-9708Debt Debt-to-Equity Ratio1.24 Current Ratio2.02 Quick Ratio2.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book1.36Profitability EPS (Most Recent Fiscal Year)($16.48) Net Income$-221,570,000.00 Net MarginsN/A Return on Equity-416.05% Return on Assets-124.55%Miscellaneous Employees45 Outstanding Shares22,780,000Market Cap$163.79 million Next Earnings Date6/10/2019 (Estimated) OptionableOptionable Axovant Gene Therapies (NASDAQ:AXGT) Frequently Asked Questions What is Axovant Gene Therapies' stock symbol? Axovant Gene Therapies trades on the NASDAQ under the ticker symbol "AXGT." When did Axovant Gene Therapies' stock split? How did Axovant Gene Therapies' stock split work? Axovant Gene Therapies's stock reverse split before market open on Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Axovant Gene Therapies stock prior to the reverse split would have 13 shares after the split. When is Axovant Gene Therapies' next earnings date? Axovant Gene Therapies is scheduled to release their next quarterly earnings announcement on Monday, June 10th 2019. View Earnings Estimates for Axovant Gene Therapies. What price target have analysts set for AXGT? 6 brokers have issued twelve-month price targets for Axovant Gene Therapies' stock. Their predictions range from $32.00 to $56.00. On average, they expect Axovant Gene Therapies' stock price to reach $48.00 in the next year. This suggests a possible upside of 567.6% from the stock's current price. View Analyst Price Targets for Axovant Gene Therapies. What is the consensus analysts' recommendation for Axovant Gene Therapies? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Gene Therapies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Gene Therapies. What are Wall Street analysts saying about Axovant Gene Therapies stock? Here are some recent quotes from research analysts about Axovant Gene Therapies stock: 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (5/14/2019) 2. Cowen Inc analysts commented, ". We reiterate our Overweight rating and $221 Price Target. Amgen posted an strong top-line at $5.56B vs Bloomberg consensus of $5.51B and a bottom-line beat with EPS of $3.56 vs consensus of $3.49. This also included the ASR of $3B in 1Q 2019. Key update was raising of the low end of revenue and EPS guidance, so range is now $22.0-22.9B and $13.25-14.30/sh from $21.8-22.9B and $13.10-$14.30/sh previously based on 1Q results. Though the company noted this reflects a range of outcomes for Sensipar, this adjustment suggests it had been accounting for the potential for additional top-line pressure in 1Q." (5/1/2019) 3. HC Wainwright analysts commented, "Our price target of $7/share is based on an equally-weighted composite of: (a) $5.56/share, as a 35x multiple of taxed and diluted $1.70 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $9.23/ share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (3/12/2019) 4. Chardan Capital analysts commented, "We upgrade Buy (low conviction), maintaining our price target at $4/share. This morning, Axovant announced updates from 2 of its clinical programs, showing: (1) encouraging interim results at 3 months from Cohort 1 (lower dose of 4.2×10^6 the phase II SUNRISE-PD trial (NCT03720418) of AXO-Lenti-PD gene therapy (GT) in Parkinson’s disease (PD), and (2) 3- month data showing enzyme activity in an investigator-initiated study (dose of 1.0x 10^14 vg) of AXO-AAV-GM2 GT in Tay-Sachs disease." (3/11/2019) Has Axovant Gene Therapies been receiving favorable news coverage? Headlines about AXGT stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axovant Gene Therapies earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Axovant Gene Therapies' key competitors? Some companies that are related to Axovant Gene Therapies include Emisphere Technologies (EMIS), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), Stemline Therapeutics (STML), Organogenesis (ORGO), Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Crinetics Pharmaceuticals (CRNX), CannTrust (CTST), Akebia Therapeutics (AKBA), Lexicon Pharmaceuticals (LXRX), Aurinia Pharmaceuticals (AUPH), Kura Oncology (KURA), Viking Therapeutics (VKTX) and Puma Biotechnology (PBYI). What other stocks do shareholders of Axovant Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Gene Therapies investors own include Conatus Pharmaceuticals (CNAT), Abeona Therapeutics (ABEO), Agile Therapeutics (AGRX), Fibrocell Science (FCSC), Lexicon Pharmaceuticals (LXRX), The Medicines (MDCO), Nabriva Therapeutics (NBRV), Ocular Therapeutix (OCUL), Zynerba Pharmaceuticals (ZYNE) and AT&T (T). Who are Axovant Gene Therapies' key executives? Axovant Gene Therapies' management team includes the folowing people: Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)Dr. David T. Hung M.D., Scientific Advisor of Group (Age 61)Dr. Fraser Wright, Chief Technology OfficerMs. Tricia Truehart, Head of Investor Relations Who are Axovant Gene Therapies' major shareholders? Axovant Gene Therapies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (11.32%), Jefferies Group LLC (11.07%), Primecap Management Co. CA (4.62%), Macquarie Group Ltd. (3.80%), Morgan Stanley (0.96%) and Marshall Wace LLP (0.90%). Which major investors are buying Axovant Gene Therapies stock? AXGT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jefferies Group LLC, Primecap Management Co. CA, Macquarie Group Ltd., Morgan Stanley, Marshall Wace LLP, Jane Street Group LLC and ExodusPoint Capital Management LP. How do I buy shares of Axovant Gene Therapies? Shares of AXGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Axovant Gene Therapies' stock price today? One share of AXGT stock can currently be purchased for approximately $7.19. How big of a company is Axovant Gene Therapies? Axovant Gene Therapies has a market capitalization of $163.79 million. The company earns $-221,570,000.00 in net income (profit) each year or ($16.48) on an earnings per share basis. Axovant Gene Therapies employs 45 workers across the globe. What is Axovant Gene Therapies' official website? The official website for Axovant Gene Therapies is http://www.axovant.com/. How can I contact Axovant Gene Therapies? Axovant Gene Therapies' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The company can be reached via phone at 44-20-3318-9708. MarketBeat Community Rating for Axovant Gene Therapies (NASDAQ AXGT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 13 (Vote Outperform)Underperform Votes: 12 (Vote Underperform)Total Votes: 25MarketBeat's community ratings are surveys of what our community members think about Axovant Gene Therapies and other stocks. Vote "Outperform" if you believe AXGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of investing in REITs? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.